BG-12
BG-12 (BG00012, Dimethyl Fumarate) is an investigational oral therapy in Phase III clinical development as a monotherapy for the treatment of Relapsing-Remitting Multiple Sclerosis (RRMS), in Phase II clinical development for Rheumatoid Arthritis (RA).
BG-12 received Fast Track designation in MS from the U.S. Food and Drug Administration (FDA), which may expedite U.S. regulatory review. Biogen Idec retains full worldwide commercial rights to BG-12.
Both U.S. and European regulators have accepted for review Biogen Idec’s application for experimental Multiple Sclerosis drug BG-12, the company said on Wednesday.
The pill is seen by some Wall Street analysis as having the potential to become the world’s leading treatment for the chronic, disabling disease that attacks the central nervous system and can lead to numbness, paralysis and loss of vision.
The company said the U.S. Food and Drug Administration granted a standard 10-month review for BG-12 and the European regulatory agency has validated its application. Both applications were submitted in the first quarter of 2012. We’ll keep our eyes peeled out for it, and update you with our thoughts on it as more info. is released.
Source: Suddenly MS
..
Please note that all comments are moderated.
So that you can be kept up to date with MS information
Become a Member of MS Views and News
Become a Member of MS Views and News
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
Visit our MS Learning Channel on YouTube: http://www.youtube.com/msviewsandnews